Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDApellis Pharmaceuticals Inc Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 12 | -$0.45 | -$0.12 | -$0.27 |
| Q2 2026 | 11 | -$0.46 | -$0.15 | -$0.31 |
| Q3 2026 | 11 | -$0.50 | -$0.08 | -$0.26 |
| Q4 2026 | 4 | -$0.20 | -$0.17 | -$0.18 |
| Q1 2027 | 4 | -$0.29 | -$0.25 | -$0.27 |
| Q2 2027 | 5 | -$0.19 | -$0.16 | -$0.18 |
| Q3 2027 | 8 | -$0.19 | -$0.16 | -$0.17 |
| Q4 2027 | 4 | -$0.19 | -$0.16 | -$0.17 |
| Q1 2028 | 5 | $1.14 | $1.32 | $1.23 |
| Q2 2028 | 7 | $1.31 | $1.52 | $1.41 |
| Q3 2028 | 10 | $1.42 | $1.65 | $1.53 |
Apellis Pharmaceuticals Inc Earnings Date And Information
Apellis Pharmaceuticals Inc last posted its earnings results on Thursday, May 7th, 2026. The company reported $0.15 earnings per share for the quarter, topping analysts' consensus estimates of $-0.32915 by $0.47915. The company had revenue of 268.30 M for the quarter and had revenue of 1.00 B for the year. Apellis Pharmaceuticals Inc has generated $0 earnings per share over the last year ($0.18 diluted earnings per share) and currently has a price-to-earnings ratio of 38.8. Apellis Pharmaceuticals Inc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Apellis Pharmaceuticals Inc Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 05/07/2026 | Q1 2026 | -$0.33 | $0.15 | 0.48 | $211.35 M | $268.30 M |
| 02/24/2026 | Q4 2025 | -$0.39 | -$0.47 | -0.08 | $199.39 M | $199.91 M |
| 10/30/2025 | Q3 2025 | $1.03 | $1.71 | 0.68 | $453.57 M | $458.58 M |
| 07/31/2025 | Q2 2025 | -$0.44 | -$0.33 | 0.11 | $185.46 M | $178.49 M |
| 05/07/2025 | Q1 2025 | -$0.36 | -$0.74 | -0.38 | $193.97 M | $166.80 M |
| 02/28/2025 | Q4 2024 | -$0.37 | -$0.29 | 0.08 | $198.80 M | $212.53 M |
| 11/05/2024 | Q3 2024 | -$0.32 | -$0.46 | -0.14 | $200.00 M | $196.83 M |
| 08/01/2024 | Q2 2024 | -$0.33 | -$0.30 | 0.03 | $190.89 M | $199.69 M |
| 05/07/2024 | Q1 2024 | -$0.54 | -$0.54 | 0 | $163.27 M | $172.33 M |
| 02/27/2024 | Q4 2023 | -$0.66 | -$0.73 | -0.07 | N/A | $146.38 M |
| 11/01/2023 | Q3 2023 | -$0.84 | -$1.17 | -0.33 | N/A | $110.40 M |
| 07/31/2023 | Q2 2023 | -$1.35 | -$1.02 | 0.33 | N/A | $94.97 M |
| 05/04/2023 | Q1 2023 | -$1.42 | -$1.56 | -0.14 | N/A | $44.85 M |
| 02/21/2023 | Q4 2022 | -$1.65 | -$1.50 | 0.15 | N/A | $22.66 M |
| 11/07/2022 | Q3 2022 | -$1.48 | -$1.75 | -0.27 | N/A | $22.06 M |
| 08/08/2022 | Q2 2022 | -$1.43 | -$1.46 | -0.03 | N/A | $16.32 M |
| 05/04/2022 | Q1 2022 | -$1.36 | -$1.42 | -0.06 | N/A | $14.38 M |
| 02/28/2022 | Q4 2021 | -$1.32 | -$1.73 | -0.41 | N/A | $60.29 M |
| 11/08/2021 | Q3 2021 | -$1.73 | -$2.28 | -0.55 | N/A | $5.65 M |
| 08/09/2021 | Q2 2021 | -$1.70 | -$2.72 | -1.02 | N/A | $623.00 K |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Apellis Pharmaceuticals Inc Earnings: FAQ's
In the previous quarter, Apellis Pharmaceuticals Inc (:APLS) reported $0.15 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.32915 by $0.47915.
The conference call for Apellis Pharmaceuticals Inc's latest earnings report can be listened to online.
The conference call transcript for Apellis Pharmaceuticals Inc's latest earnings report can be read online.
Apellis Pharmaceuticals Inc (:APLS) has a recorded annual revenue of $1.00 B.
Apellis Pharmaceuticals Inc (:APLS) has a recorded net income of $22.39 M.Apellis Pharmaceuticals Inc has generated $0.18 earnings per share over the last four quarters.
Apellis Pharmaceuticals Inc (:APLS) has a price-to-earnings ratio of 38.8 and price/earnings-to-growth ratio is 0.07.